Search

Search Constraints

You searched for: Author/Creator Collins, Steven

Search Results

3. [F1–02–01]: DIAGNOSTIC AND PROGNOSTIC POWER OF FLUID AND NEUROIMAGING MARKERS OF PATHOLOGY AND NEURODEGENERATION: THE ALZHEIMER'S IMAGING, BIOMARKERS, AND LIFESTYLE (AIBL) STUDY OF AGEING EXPERIENCE. (1st July 2017)

4. [O1–06–04]: CSF P‐TAU IS CORRELATED WITH TAU PET, WHILE Aβ PET CORRELATES WITH Aβ1–42 AND THE T‐TAU/Aβ1–42 RATIO. (1st July 2017)

5. [P1–416]: CSF TOTAL TAU AS A BIOMARKER FOR NEURONAL INJURY IN ALZHEIMER's DISEASE: ALIGNING RATES OF CSF CHANGE WITH RATES OF HIPPOCAMPAL AND CORTICAL GRAY MATTER ATROPHY. (1st July 2017)

6. A pilot study of the utility of cerebrospinal fluid neurofilament light chain in differentiating neurodegenerative from psychiatric disorders: A 'C-reactive protein' for psychiatrists and neurologists?. (January 2020)

7. Alzheimer's disease cerebrospinal fluid biomarkers are not influenced by gravity drip or aspiration extraction methodology. Issue 1 (December 2015)

8. Amyloid-β (Aβ)-Related Cerebral Amyloid Angiopathy Causing Lobar Hemorrhage Decades After Childhood Neurosurgery. Issue 8 (30th June 2022)

9. Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease. Issue 3 (March 2021)

10. Cerebrospinal fluid Alzheimer disease biomarkers for assessing cognitive and neuropsychiatric symptoms: Expanding the 'toolkit' in the psychiatrist's diagnostic armamentarium. (July 2022)